X

Trial Profile

A Double-Blinded, Randomized, Placebo-Controlled, Phase 2B Trial of IMC-1 for the Treatment of Fibromyalgia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib/famciclovir (Primary)
Indications Fibromyalgia
Focus Registrational; Therapeutic Use
Acronyms FORTRESS
Sponsors Virios Therapeutics

Most Recent Events

29 Nov 2022 According to a Virios Therapeutics media release, Greg Duncan, Chairman and CEO of the company will be attending and presenting at the Planet MicroCap Showcase. The presentation will focus on the post-hoc analysis from this study.
25 Sep 2022 Status changed from active, no longer recruiting to completed.
19 Sep 2022 Primary endpoint (pain reduction) has been met, according to a Virios Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com